未登录 Efficacy and Safety of CT-P43, a Candidate Ustekinumab Biosimilar, in Moderate-to-Severe Plaque Psoriasis: 52-Week Results From a Randomised, Active-Controlled, Double-Blind, Phase III Study CT-P43（一种乌司木单抗生物类似药候选药物）在斑块状银屑病（中度至重度）中的有效性与安全性：一项随机、活性对照、双盲、III期研究的52周结果 Papp, Kim A.; Jaworski, Janusz; Kwiek, Bartlomiej; Trefler, Jakub; Dudek, Anna; Szepietowski, Jacek C.; Reznichenko, Nataliya; Narbutt, Joanna; Baran, Wojciech; Kolinek, Joanna; Daniluk, Stefan; Bartnicka-Maslowska, Katarzyna; Reich, Adam; Andrashko, Yuriy; Kim, Sunghyun; Bae, Yunju; Jeon, Dabee; Jung, Jinsun; Lee, Hyunseung; Ko, Woori; Kim, Yejin; Thaci, Diamant 分享 收藏
分享 收藏
分享 收藏
分享 收藏
CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study Pariser, David M.; Lebwohl, Mark G.; Jaworski, Janusz; Trefler, Jakub; Daniluk, Stefan; Dudek, Anna; Baran, Wojciech; Owczarek, Witold; Brzewski, Pawel; Sikora, Mariusz; Krogulec, Marek; Kim, Sunghyun; Suh, Jeehye; Choi, Eunjin; Cha, Jungbin; Lee, Hyunjin; Lee, Sungjeong; Koo, John Y. 分享 收藏
Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study Lebwohl, Mark G.; Koo, John Y.; Jaworski, Janusz; Trefler, Jakub; Daniluk, Stefan; Dudek, Anna; Baran, Wojciech; Owczarek, Witold; Kolinek, Joanna; Brzewski, Pawel; Sikora, Mariusz; Krogulec, Marek; Kim, Sunghyun; Bae, Yunju; Jeon, Dabee; Choi, Eunjin; Cha, Jungbin; Lee, Hyunjin; Choi, Sujin; Pariser, David M. 分享 收藏
Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study Burmester, Gerd; Klimiuk, Piotr Adrian; Trefler, Jakub; Jaworski, Janusz; Kim, Sunghyun; Bae, Yunju; Jeon, Dabee; Lee, Hyunseung; Jang, Jiyoung; Hwang, Chankyoung; Lee, Hojae; Smolen, Josef S. 分享 收藏
PHARMACOKINETICS, USABILITY AND SAFETY OF TOCILIZUMAB BIOSIMILAR (CT-P47) ADMINISTERED SUBCUTANEOUSLY BY AUTO-INJECTOR OR PRE- FILLED SYRINGE 托珠单抗生物类似药（CT-P47）经自动注射器或预充式注射器皮下给药的药代动力学、可用性和安全性 Keystone, E.; Burmester, G. R.; Smolen, J. S.; Yu, K. S.; Ryu, H.; Shin, D.; Park, M.; Hwang, J.; Moon, S. J.; Kim, M.; Klimiuk, P. A.; Trefler, J.; Jaworski, J.; Kim, S. H.; Bae, Y.; Jeon, D.; Lee, H.; Jang, J.; Bae, J. 分享 收藏
SIMILAR EFFICACY, SAFETY, AND IMMUNOGENICITY OFTOCILIZUMAB BIOSIMILAR (CT-P47) AND REFERENCE TOCILIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS: WEEK 32 RESULTS FROM THE PHASE III SINGLE TRANSITION STUDY 中度至重度活动性类风湿关节炎患者中，曲妥珠单抗生物类似药（CT-P47）与参比曲妥珠单抗具有相似的有效性、安全性和免疫原性：III期单过渡研究的第32周结果 Smolen, J. S.; Trefler, J.; Racewicz, A.; Jaworski, J.; Zielinska, A.; Krogulec, M.; Jeka, S.; Wojciechowski, R.; Kolossa, K.; Dudek, A.; Krajewska-Wlodarczyk, M.; Hrycaj, P.; Klimiuk, P. A.; Burmester, G. R.; Kim, S. H.; Bae, Y.; Jeon, D.; Yang, G.; Jung, Y.; Hong, J.; Keystone, E. 分享 收藏
分享 收藏
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study Papp, Kim A.; Lebwohl, Mark G.; Thaci, Diamant; Jaworski, Janusz; Kwiek, Bartlomiej; Trefler, Jakub; Dudek, Anna; Szepietowski, Jacek C.; Reznichenko, Nataliya; Narbutt, Joanna; Baran, Wojciech; Kolinek, Joanna; Daniluk, Stefan; Bartnicka-Maslowska, Katarzyna; Reich, Adam; Andrashko, Yuriy; Kim, Sunghyun; Bae, Yunju; Jeon, Dabee; Jung, Jinsun; Lee, Hyunseung; Pyo, Tina; Ko, Woori 分享 收藏
Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial Suh, Chang-Hee; Yoo, Dae Hyun; Berrocal Kasay, Alfredo; Chalouhi El-Khouri, Elia; Cons Molina, Francisco Fidenci; Shesternya, Pavel; Miranda, Pedro; Medina-Rodriguez, Francisco G.; Wiland, Piotr; Jeka, Slawomir; Chavez-Corrales, Jose; Linde, Thomas; Hrycaj, Pawel; Abello-Banfi, Mauricio; Hospodarskyy, Ihor; Jaworski, Janusz; Piotrowski, Mariusz; Brzosko, Marek; Krogulec, Marek; Shevchuk, Sergii; Calvo, Armando; Andersone, Daina; Park, Won; Shim, Seung Cheol; Lee, Sang Joon; Lee, Sung Young 分享 收藏
Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis Fifty-Two-Week Phase III Randomized Study Results Weinblatt, Michael E.; Baranauskaite, Asta; Dokoupilova, Eva; Zielinska, Agnieszka; Jaworski, Janusz; Racewicz, Artur; Pileckyte, Margarita; Jedrychowicz-Rosiak, Krystyna; Baek, Inyoung; Ghil, Jeehoon 分享 收藏
Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis Weinblatt, Michael E.; Baranauskaite, Asta; Niebrzydowski, Jaroslaw; Dokoupilova, Eva; Zielinska, Agnieszka; Jaworski, Janusz; Racewicz, Artur; Pileckyte, Margarita; Jedrychowicz-Rosiak, Krystyna; Cheong, Soo Yeon; Ghil, Jeehoon 分享 收藏
RANDOMISED DOUBLE-BLIND STUDY SHOWS COMPARABLE LONG-TERM EFFICACY AND SAFETY BETWEEN RITUXIMAB BIOSIMILAR CT-P10 AND INNOVATOR RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 48-WEEK RESULTS Suh, C. -H.; El Khouri, E. Chalouhi; Miranda, P.; Molina, F. F. Cons; Shesternya, P.; Medina-Rodriguez, F.; Wiland, P.; Jeka, S.; Chavez-Corrales, J.; Linde, T.; Hrycaj, P.; Hospodarskyy, I.; Abello-Banfi, M.; Jaworski, J.; Piotrowski, M.; Park, W.; Shim, S. C.; Lee, S. J.; Lee, S. Y.; Yoo, D. H. 分享 收藏
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study Yoo, Dae Hyun; Prodanovic, Nenad; Jaworski, Janusz; Miranda, Pedro; Ramiterre, Edgar; Lanzon, Allan; Baranauskaite, Asta; Wiland, Piotr; Abud-Mendoza, Carlos; Oparanov, Boycho; Smiyan, Svitlana; Kim, HoUng; Lee, Sang Joon; Kim, SuYeon; Park, Won 分享 收藏
SUSTAINED EFFICACY AND COMPARABLE SAFETY AND IMMUNOGENICITY AFTER TRANSITION TO SB5 (AN ADALIMUMAB BIOSIMILAR) VS CONTINUATION OF THE ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULT OF PHASE III STUDY Weinblatt, M.; Baranauskaite, A.; Niebrzydowski, J.; Dokoupilova, E.; Zielinska, A.; Sitek-Ziolkowska, K.; Jaworski, J.; Racewicz, A.; Pileckyte, M.; Jedrychowicz-Rosiak, K.; Zhdan, V.; Cheong, S. Y.; Ghil, J. 分享 收藏
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3) Edwards, Christopher J.; Blanco, Francisco J.; Crowley, Jeffrey; Birbara, Charles A.; Jaworski, Janusz; Aelion, Jacob; Stevens, Randall M.; Vessey, Adele; Zhan, Xiaojiang; Bird, Paul 分享 收藏
DISEASE ACTIVITY ASSESSMENT USING THE DAS28, CDAI AND SDAI AND EFFECT OF ANTI-DRUG ANTIBODY ON CLINICAL RESPONSE IN A RANDOMIZED, DOUBLE-BLIND, COMPARATIVE TRIAL OF CT-P13 AND INNOVATOR INFLIXIMAB: PLANETRA STUDY Yoo, D. -H.; Park, W.; Brzosko, M.; Geher, P.; Andersone, D.; Jaworski, J.; Rekalov, D.; Oparanov, B.; Kausiene, R.; Pacheco-Tena, C.; Lee, S. 分享 收藏
分享 收藏
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
.png){kind=icon}
分享.png){kind=icon}
收藏